Bristol Myers Pays $250M Milestone to Sichuan Biokin Unit for IZA-BREN
BMY sits 48% above its 52-week low of $42.52 on elevated volume (3.3× avg).
Summary
Bristol Myers Squibb has paid a $250 million milestone to Sichuan Biokin Pharmaceutical's unit under the IZA-BREN agreement. This is a significant development payment, indicating progress in the partnered program. The payment is material relative to BMY's R&D spending and signals advancement of the collaboration. No further details on the milestone trigger were provided.
At the time of this announcement, BMY was trading at $62.99 on NYSE in the Life Sciences sector, with a market capitalization of approximately $128.8B. The 52-week trading range was $42.52 to $68.64. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.